BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8011 related articles for article (PubMed ID: 2456315)

  • 21. Nevi, other than dysplastic and Spitz nevi.
    Cochran AJ; Bailly C; Paul E; Dolbeau D
    Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunohistochemical study of nevocellular nevi].
    Nakamura S
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):709-16. PubMed ID: 2685414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study.
    Palazzo J; Duray PH
    Hum Pathol; 1989 Apr; 20(4):341-6. PubMed ID: 2703228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies.
    Lazzaro B; Strassburg A
    Hybridoma; 1996 Apr; 15(2):141-6. PubMed ID: 8743294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pattern of HMB-45 antibody staining in compound Spitz nevi.
    Bergman R; Dromi R; Trau H; Cohen I; Lichtig C
    Am J Dermatopathol; 1995 Dec; 17(6):542-6. PubMed ID: 8599465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness.
    Sagebiel RW
    J Invest Dermatol; 1993 Mar; 100(3):322S-325S. PubMed ID: 8440914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysplastic melanocytic nevus. Immunohistochemical heterogeneity by melanosomal markers and S-100.
    Salopek TG; Jimbow K
    Am J Dermatopathol; 1991 Apr; 13(2):130-6. PubMed ID: 1709340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotype and possible origin of nevi with phenotypical heterogeneity.
    Winnepenninckx V; van den Oord JJ
    Arch Dermatol Res; 2004 Jul; 296(2):49-53. PubMed ID: 15141316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
    Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
    J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells.
    Kopera D; Hohenleutner U; Stolz W; Landthaler M
    Dermatology; 1997; 194(4):344-50. PubMed ID: 9252755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
    Holt JB; Sangueza OP; Levine EA; Shen P; Bergman S; Geisinger KR; Creager AJ
    Am J Clin Pathol; 2004 Jan; 121(1):58-63. PubMed ID: 14750241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas.
    Gray MH; Smoller BR; McNutt NS; Hsu A
    Arch Dermatol; 1990 Apr; 126(4):472-6. PubMed ID: 1690969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application.
    Nakajima T; Watanabe S; Sato Y; Kameya T; Shimosato Y; Ishihara K
    Cancer; 1982 Sep; 50(5):912-8. PubMed ID: 6807528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
    Maeda K; Jimbow K
    Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral melanocytic lesions: differences in expression of HMB-45 and S-100 antigens in round and spindle cells of malignant and benign lesions.
    Gazit D; Daniels TE
    J Oral Pathol Med; 1994 Feb; 23(2):60-4. PubMed ID: 8164154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells.
    Liao SK; Smith JW; Kwong PC; Natali PG; Kusama M; Hamby CV; Ferrone S
    Cancer Res; 1987 Sep; 47(18):4835-41. PubMed ID: 3476198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiomatous type of intradermal nevi.
    Söderström KO
    Am J Dermatopathol; 1987 Dec; 9(6):549-51. PubMed ID: 3128136
    [No Abstract]   [Full Text] [Related]  

  • 39. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurofibromas and neurotized melanocytic nevi are immunohistochemically distinct neoplasms.
    Gray MH; Smoller BR; McNutt NS; Hsu A
    Am J Dermatopathol; 1990 Jun; 12(3):234-41. PubMed ID: 1693815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 401.